Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Cancer Res. 2010 Jun 8;70(13):5249–5258. doi: 10.1158/0008-5472.CAN-09-2860

Figure 6. Leukemia-specific CTL can be in vitro primed starting with the CD3/28-expanded CB T cells.

Figure 6

T cells were first CD3/28-expanded in the presence of IL2+ IL-7 over 14 days as described and thereafter were primed/sensitized against 2 killed leukemia cell lines in parallel cultures for 7-9 days at 10:1 responder : stimulator ratio in the presence of IL-12, IL-7, and IL-15. A, CTL primed in vitro with Mitomycin C-treated IM9 cells. B, CTL primed in vitro with IFNγ-treated and Mitomycin C-treated U937 cells. Each CTL culture was re-stimulated 2 more times (1st IL7+ IL-15, thereafter 2nd in IL15 alone) for a total of 3 weeks with their respective killed leukemia cells. Cytotoxicity of washed effectors after 3 weeks in CTL culture was tested against fresh, unmodified, BATDA®-loaded IM9, U937 cells, and recipient PHA blasts at the indicated E:T ratios for 3h, as indicated. Europium release was measured by the Delfia® EuTDA cytotoxicity assay and the calculated percent specific cytotoxicity is presented on the Y-axis. Representative of four experiments.